AUT00201, an experimental oral small molecule being developed by Autifony Therapeutics, reduced the loss of motor neurons — the nerve cells that control movement — and eased motor symptoms in a mouse model of amyotrophic lateral sclerosis (ALS), a new study showed. It was also found to improve…
AUT00201 boosts muscle strength, coordination in ALS mouse model
After my husband Todd’s ALS diagnosis in 2010, we regularly monitored the forced vital capacity (FVC) of his lungs. This was because the neurologist at our ALS clinic had told us that if Todd wanted to get a feeding tube, he’d need to do it while his FVC was…
China’s Center for Drug Evaluation (CDE) has approved a request by Zhimeng Biopharma to launch a Phase 2/3 study of its experimental therapy CB03-154 in people with amyotrophic lateral sclerosis (ALS). The oral treatment, which is designed to slow disease progression by reducing nerve cell overactivity, is also…
I used to take for granted my ability to sync up with the people and events in my life — to keep up with conversations, move in unison with my fellow dancers, and show up on time. But that was before ALS waltzed into my life. At first, the…
Anita Newton is a retired science teacher who lives near Bristol, England. She taught chemistry for 30 years before retiring when her husband, Craig, was diagnosed with ALS. Her interests range from sports like pickleball, badminton, and table tennis to reading, writing, painting, and crafting. She also enjoys traveling…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Klotho Neurosciences’ gene therapy candidate for amyotrophic lateral sclerosis (ALS). The designation is intended to boost the development of potential treatments for rare diseases, or those that impact fewer than 200,000 people in the U.S. It…
A new treatment approach that noninvasively delivers gentle electrical stimulation to the spinal cord and peripheral nerves — the nerves that connect the brain and spinal cord to the rest of the body — was found to slow disease progression and extend survival in a mouse model of amyotrophic…
A coalition of amyotrophic lateral sclerosis (ALS) patients and their family members has filed a petition to the U.S. Food and Drug Administration (FDA) asking the agency to review again available data for the stem cell therapy NurOwn (debamestrocel). The petitioners include ALS patients who received NurOwn in…
In 2012, two years after my husband, Todd, was diagnosed with ALS, he and I made a trip to a larger town a couple hours away to pick out fixtures and appliances for our new accessible home. After purchasing the items and scheduling the delivery, we headed back to…
Neurizon Therapeutics has entered into a global licensing deal with Elanco Animal Health to advance the development of NUZ-001, an investigational therapy for amyotrophic lateral sclerosis (ALS). Monepantel, the active ingredient in NUZ-001, is an oral deworming agent commonly used in veterinary medicine, and Elanco, a company that…
Recent Posts
- In life with ALS, we find moments of ‘genius’ to keep our minds active
- Brain imaging agent shows promise for detecting toxic ALS protein
- I reframed my life with ALS by becoming a calmer duck
- New ALS treatment improves survival, leads to function gains in trial
- ALS Network, ALS United calling for ‘bold’ research proposals for funding